{"text_format":"3","workbook":"xlsx","n_sheets":1,"sheets":[" Table 1 with detail"],"read":"whole","date_system":"1900"}

{"sheet":" Table 1 with detail","index":0,"n_rows":91,"n_cols":12,"rows_kept":91}
["Ref #","Author, year","Design","Population","Smoking cessation intervention setting","Matrix","Smoking cessation intervention ","Health outcomes \n(only primary)","Smoking cessation implementation outcomes","Smoking cessation barriers/Facilitators","Smoking cessation implementation strategies","担当者"]
[null,"Ito et al., 2006","Randomized trial","617 smokers from first-visit outpatients at one hospital","Clinical","I-4. Others\n","Feedback of genetic information regarding an L-myc polymorphism (marker for tumor prognosis with lung and possibly other types\nof cancers)","Abstinence at nine months \nContinuous abstinence \nNew abstinence ","Not applicable (NA)","NA","NA","今村"]
[null,"Goto et al., 2011","Cross-sectional / discrete choice experiment","6,515 consumer monitors\n616 current smokers (2006) \n600 current smokers (2010)","NA","PH2-1. Smoke-free policies\nPublic awareness about tobacco consumption risk and benefits of tobacco cessation","Price of cigarettes, Penalty with fine for smoking in public places, Overall mortality risk (relative risk of nonsmokers), Duration of bed rest caused by upper respiratory\ntract infection, Risk of lung cancer caused by secondhand smoking ","Intention to quit or continue to smoke","NA","NA","NA","今村"]
[null,"Taniguchi et al., 2019","Prospective cohort","77 human immunodeficiency virus (HIV)-positive male and 323 HIV-negative male with complications","Clinical (HIV-designated)","I-4. Behavioral counseling and cessation medication\n\n","Smoking cessation therapy (SCT) covered by the Japanese medical insurance system","Quit smoking for at least the previous two weeks,  validation: Carbon Monoxide (CO)","NA","NA","NA","今村"]
[null,"Nomura et al., 2019","Randomized trial","115 nicotine-dependent adults","Clinical","I-4. Web or internet-based intervention\n\n","An internet-based remote smoking cessation support program","Continuous abstinence  from weeks 9 to 12","NA","NA","NA","今村"]
[null,"Igarashi et al., 2016","Simulation\n","1,261 Japanese adults, who were current or former smokers at the time of the survey (June 2013), completed a web-based questionnaire","NA (simulation)","I-4. Behavioral counseling and cessation medication\n\n","1) Varenicline, \n2) Nicotine Replacement Therapy (NRT)\n3) Behavioral modification therapy (BMT) \n4) Unassisted attempts\n","NA","NA","NA","NA","今村"]
[null,"Igarashi et al., 2009","Simulation\n","39,098,100 men and 41,003,000 women aged betweeen 30 and 70","NA (simulation)","I-4. Behavioral counseling and cessation medication\n\n","Smoking-cessation counselling by a physician compared to\nuse of varenicline","NA","NA","NA","NA","今村"]
[null,"Otsu et al., 2012","Randomized trial","94 patients who went for follow-up visits to one Japanese clinic, which specialized in cardiovascular internal medicine, that were diagnosed with chronic heart failure (CHF)","Clinical","I-4. Behavioral counseling and cessation medication\n\n","A comprehensive educational program for CHF for six months, self-monitoring","Death due to CHF,\nhospital admission due to CHF, brain natriuretic peptide (BNP) data, New York Heart Association (NYHA) level, blood pressure, pressure pulse, weight and deteriorating\nsymptoms related to CHF","NA","NA","NA","今村"]
[null,"Fujioka et al., 2012","Descriptive","52 pregnant smokers in the first trimester of pregnancy","Clinical","I-4. Behavioral counseling and cessation medication\n","A 3 month e-learning cessation smoking-support program (ECP)\n1) face-to-face support for their attempts to quit smoking at their regular obstetric health check-up.\n2)the electronic component of the non-smoking education program\n3) breath tested for their carbon monoxide levels","Achievement rate of non-smoking,  validation: CO","NA","NA","NA","今村"]
[null,"Hashimoto et al., 2015","Cross-sectional","612 directors of Japanese mental health hospitals","Clinical","PH2-4. Smoke-free policies\n","Smoking bans in mental health hospitals",null,"Adoption: Prevalence of comprehensive smoking bans","<Relative advantage>\n・Concerns that increase the incidence of surreptitious smoking, staff opposition\n・Concern about incidence of smoking around hospital grounds\n・Concern that introducing smoking ban would exacerbate patients’ psychiatric symptoms\n<Patient needs & resources>\nStaff opposition ","NA","今村"]
[null,"Lally, Robin M. et al., 2008","Cross-sectional  survey","100 oncology nurses in Japan","Clinical","I-4. Others ","Brief talk regarding smoking cessation with their patients who smoke","NA","NA","NA","NA","齋藤/今村"]
[null,"Ohmi et al., 2013","Cross-sectional survey","56 teachers and office workers  and 449 students in Nayoro City University","School","PH2-3. Smoke-free policies","A smoking policy that includes a total ban on smoking both indoors and outdoors on campus\n","The number of cigarettes\nsmoked per day, years of smoking, items from the Fagerstrom Test for Nicotine Dependence (FTND), abstinence,  intention to quit.","NA","NA","NA","今村"]
[null,"Hotta et al., 2007","Prospective cohort","101 employees of Okayama University","School","I-2. Behavioral counseling and cessation medication\nWeb or internet-based intervention","Intensive cessation programme delivered in a group format\n1) nicotine patch therapy\n2) internet mailing supports for the university employees\n3) face-to-face discussion meetings\n4) regular assessment about compliance, toxicity, and smoking status through these direct interviews ","Abstinence rate from smoking","NA","NA","NA","今村"]
[null,"Kadowaki et al., 2005","Prospective cohort","Male workers in a radiator manufacturing factory in Shiga\n- 202 baseline smokers were included in the analysis of the time period of health education\n- 170 baseline smokers were included in the analysis of the time period of environmental changes","Workplace","PH2-2. Smoke-free policies\nI-2.Behavioral counseling and cessation medication","A five-month intervention programme\n1)  individual advice\n2) self-help materials\n3) group sessions\nEnvironmental change\n1) tax increase\n2) indoor smoking ban","Smoking cessation rates at the end of each time period","NA","NA","NA","今村"]
[null,"Taniguchi et al., 2018","Prospective cohort","488 smokers who visited these six smoking cessation clinics"," Clinical","I-4. Behavioral counseling and cessation medication","Smoking cessation therapy\n(SCT) that consisted of five sessions","Self‐report of at least two weeks of smoking abstinence,  validation: CO","NA","NA","NA","今村"]
[null,"Tabuchi et al., 2017","Prospective cohort","1,320 smokers who initially visited these six smoking cessation clinics for the first time between October 2008 and May 2014\n541 participants who succeeded in quitting smoking at the end of the intervention"," Clinical","I-4. Behavioral counseling and cessation medication","Smoking cessation intervention five times with nurse counseling behavioural and practical counselling by nurse","Self-reported to having quit smoking for at least the previous two weeks at the end of the intervention, validation: CO","NA","NA","NA","今村"]
[null,"Tabuchi et al., 2014","A pseudo cohort study using national cross-sections","Male public workers (n = 10, 143–12,791 in 2001, 7,922–9,188 in 2004, 8,416–8,972 in 2007, and 6,840–7,750 in 2010)\nHusbands of female non-smoking public workers (n = 1, 449–1,913 in 2001, 1,499–1,853 in 2004, 1,996–2,217 in 2007, and 1,994–2,174 in 2010)","Workplace","PH2-2. Smoke-free policies\n","Smoking ban in Japanese governments’ buildings\n1) a complete workplace indoor smoking ban\n2) a partial smoking ban","Current smoker prevalence","NA","NA","NA","今村"]
[null,"Takagi et al., 2017","Randomized trial","126 patients who visited a smoking cessation clinic during the enrollment period (from December 2010 to September 2011)\n"," Clinical","I-4. Behavioral counseling and cessation medication","・The standardized smoking cessation program (Visits 1–5 for 12 weeks)\n・Service Level Agreement (SLA) assessment","Sustained abstinence at visit 5,  validation: CO","NA","NA","NA","梶"]
[null,"Li et al., 2019","Prospective cohort","153 patients attended smoking cessation outpatients of several hospitals or smoking cessation clinics"," Clinical","I-4. Behavioral counseling and cessation medication","Financial smoking cessation treatment (SCT) program based on exhaled carbon monoxide (CO)\nMedication treatment consisting of varenicline behavioral counselling from physicians and nurses","At least  four previous weeks of smoking abstinence at the end of the SCT program (12 weeks) by self-report, , verified by CO","NA","NA","NA","今村"]
[null,"Haresaku et al., 2010","Prospective cohort","580 students  in 2003 and 554 students in 2006","School","PH2-3. Public awareness about tobacco consumption risk and benefits of tobacco cessation","Tobacco curriculum\n1) Contemporary civilisation\n2) Environmental health\n3) Public health dentistry and oral epidemiology\n4) Preventive dentistry\n5) Other activities","Smoking rate","NA","NA","NA","今村"]
[null,"Katanoda et al., 2012","Simulation\n","Japanese male smokers aged 40–74 years (target population for simulation) size？\n","Health checkup center","I-4. Behavioral counseling and cessation medication","Brief intervention (BI) at health checkup facilities combined with encouraging pharmacotherapy utilization\n","Population quit rate","NA","NA","NA","梶/今村"]
[null,"Kai et al., 2008","Cross-sectional","1,063 anaesthesiologists  and thoracic surgeons "," Clinical","I-4. Behavioral counseling and cessation medication","Asking patients if they smoke \nAdvice to patients who smoke, about the health risk of smoking\nAdvice to patients who smoke, to stop smoking perioperatively\nAdvice to patients who smoke, to quit permanently\nHelping patients who smoke to stop smoking",null,"NA","NA","NA","湯脇/今村"]
[null,"Onda et al., 2019","Prospective cohort (Feasibility study)","Five smoking patients of 20 years or more who were taking medications such as antidiabetes drugs","Pharmacy","I-1.Behavioral counseling and cessation medication","Family pharmacist's Intervention for Nicotine Elimination [FINE] program: participating patients met with the pharmacists or talked to them on the phone five times at two- to four-week intervals and received personalized and structured brief smoking cessation advice.","Smoking rate, validation: CO","NA","NA","<E1.Conduct educational meetings>\nLecture(120min)\n<E3.Conduct ongoing training>\n<E7.Make training dynamic>\nProvide training course including e-learning: self-learning (180-240 min), Lecture (120 min), Practice (120 min), Follow-up during the study (120 min)","今村"]
[null,"Ino et al., 2015","Prospective cohort","1,520 grade 4 children in 30 elementary schools of the city","School","PH2-3. Public awareness about tobacco consumption risk and benefits of tobacco cessation\nI-3.Others (visit to pediatric clinic for evaluating secondhand smoke-related diseases)","Secondhand smoke screening (SSS) program\n1) questionnaire survey\n2) urinary cotinine concentration measurement\n3) pamphlet to support parental smoking cessation\n4) visit to pediatric clinic for evaluating secondhand smoke-related diseases","Parental smoking status (secondhand smoke of children), validation: urinary coninie concentration","NA","NA","NA","今村"]
[null,"Hanioka et al., 2009","Randomized trial","56 individuals who were willing to quit smoking","Dental clinic","I-4. Behavioral counseling and cessation medication","Five visits of counseling sessions\n1) set acquit date,\n2) two major regimens to prevent relapse, consisting of behavioral and pharmaceutical approaches\n3) self-help material and nicotine patches","3-, 6- and 12-month continuous abstinence rates, validation: salivary cotinine ","NA","NA","NA","今村"]
[null,"Suwa et al., 2018","Retrospective, observational study","87,329 male smokers  who had medical checkup data in the database"," Clinical","I-4. Behavioral counseling and cessation medication","Smoking cessation therapy (defined as\nthose diagnosed as “nicotine dependence” (F17.2) under the\nInternational Classification of Diseases, 10th revision (ICD-\n10))",null,"NA","NA","NA","今村"]
[null,"Masaki et al., 2019","Prospective cohort","55 patients with nicotine dependence"," Clinical","PH1-4. Clinical practice guideline\nI-4. Short text message services, \nWeb or internet-based intervention","A smartphone app of CureApp Smoking Cessation\n1) diary of smoking cessation\n2) messages and educational videos to help users quit smoking\n3) Counseling chat sessions between the users and the artificial intelligence nurse\n4) Advice for physicians","Self-reported continuous abstinence","NA","NA","NA","今村"]
[null,"Katoh et al., 2020","Review","NA","School","PH2-1. Public awareness about tobacco consumption risk and benefits of tobacco cessation","Smoking prevention classes\nProvision of information about secondhand smoking prevention on shrine grounds","Smoking rate among Hamamatsu citizens","NA","NA","NA","今村"]
[null,"Li et al., 2020","A nationwide cross-sectional study ","521 public health nurses working in 431 health centers of municipalities and special wards across the country.","Health center","I-1. Behavioral counseling and cessation medication","Prenatal smoking cessation interventions based on the 5As model ","NA","NA","NA","NA","梶"]
[null,"Kato et al., 2020","Retrospective cohort  ","177 adult smokers participating in the ascure smoking cessation program in Japan from August 2017 to August 2018. ","community? Private settings (not written)","I-1.Web or internet-based interventions","The ascure smoking cessation program （24-week completely remote, online program including six online sessions with the exclusive ascure smoking cession smartphone app.)","Abstinence during weeks 9-12 and weeks 21-24.","NA","NA","NA","梶"]
[null,"Tomioka et al., 2019","Prospective cohort ","813 patients with nicotine dependence participated in the program"," Clinical","I-4. Behavioral counseling and cessation medication","standard \"Kinengairai\" intervention\n・discussion with the attending physician\n・received either transdermal nicotine patches or varenicline \n・ returned 2, 4, 8, and 12 weeks after their baseline visit for follow-up and  CO concentration was measured, and the attending physician and a nurse with experience in smoking cessation confirmed whether smoking cessation had continued","Abstinence between the 8-week and 12-week sessions","NA","NA","NA","梶"]
[null,"Hirano et al., 2017","Cross-sectional online survey","798 eligible persons aged 20–69 years who smoked within the previous five years","NA","I-4.Behavioral counseling and cessation medication","Survey item:\nE-cigarette use\nOver the counter NRT\nSmoking cessation therapy for nicotine dependence- varenicline\nOthers unassisted","Smoking cessation","NA","NA","NA","梶/今村"]
[null,"Taniguchi et al., 2020","Prospective cohort ","889 patients who gave written informed consent to receive Japanese SCT and who answered the Tobacco Craving Index (TCI) questionnaire in the first session of the SCT "," Clinical","I-4. Behavioral counseling and cessation medication","Standard \"Kinengairai\" intervention\nConsists of a total of five sessions over 12 weeks. Patients receive smoking cessation treatment five times over 12 weeks: the first session and 2, 4, 8, and 12 weeks after the first session. Patients set a quit date one week after the first visit. At each session, patients receive medical treatment for smoking cessation by a physician for approximately 15 minutes, and behavioral counseling by nurses (15–30 minutes). Details of the Japanese SCT are available elsewhere","Abstinence according to the TCI grade at each session of Japanese SCT","NA","NA","NA","梶"]
[null,"Michibayashi et al., 2018","Semi-structured interviews","12 public health nurses from nine local governments","Community","PH2-1. Tobacco control programs","・secondhand smoking prevention\n・Smoking cessation support\n・Prevention of smoking\n・Promotion system\n（not written in detail)","NA","NA","NA","NA","梶"]
[null,"Ojima et al., 2012","Cross-sectional","11,370 patients and 739 dentists","Dental clinic","PH2-4. Smoke-free policies","No intervention","Current smoking","NA","NA","NA","今村"]
[null,"Yokoyama et al., 2014","Retrospective cohort","83 alcoholic men who were participating in an 11-week concurrent inpatient smoking cessation and alcohol abstinence program"," Clinical","PH2-4:Smoke-free policies\nI-4: behavioral counseling and cessation medication","・non-smoking facility\n・Varenicline prescription\n・Lecture for smoking cessation\n・No-smoking patrols\n・cognitive-behavioral therapy",null,"NA","NA","NA"]
[null,"Knai et al., 2021","Prospective cohort ","158 current tobacco users at a manufacturing company ","Workplace","I-2. Behavioral counseling and cessation medication","Support email distribution\nCounselling\nPharmacological support consisted of either nicotine replacement therapy or varenicline and was provided by a specialised physician according to the standard procedures for smoking cessation treatment","Self-reported abstinence of all types of nicotine-containing product use in August 2019","NA","NA","NA","湯脇"]
[null,"Nakamura et al., 2013","Case study","155 workers who smoked","Workplace","I-2. Behavioral counseling and cessation medication","・Conducted a joint introductory face-to-face counselling session at the worksite clinic. \n・Required to submit a diary on smoking cessation via email or inter-office mail once a week for a period of six months. \n・Nicotine replacement therapy was offered to participants who desired to use it or if the physician considered this therapy would be beneficial after reference to the FTND scores and/or the number of cigarettes smoked each day.","Self-reported abstinence at 24 months","NA","NA","NA","梶"]
[null,"Nakamura et al., 2018","Retrospective cohort (propensity score matching analysis)","47,745 Japanese smokers aged 40 to 74 years ","Health center","I-1. Behavioral counseling and cessation medication","Active support\n・face-to-face counseling for lifestyle modification\n・followed by repeated counseling for at least three months","Self-reported abstinence at one year","NA","NA","NA","梶"]
[null,"Tanaka et al., 2018","Prospective cohort (prospective, community-based longitudinal study)","106 chronic obstructive pulmonary disease (COPD) participants whose final analysis could be performed"," Clinical","I-4. Behavioral counseling and cessation medication","・Follow-up checkup: once per year\n・COPD classes (smoking cessation classes, health classes): four times per year\n・Patient meetings: twice per year\n・Preparation and displaying of medical posters\n・Hosting of training workshops (guidance on methods for respiratory examinations; pulmonary rehabilitation): once per year\n・Lectures and publications‡ (ongoing series); open lectures for city residents‡: once per year\n・Explanation of the results of COPD checkup to residents and medical staff: once per year\n","Questionnaires (Self-reported abstinence) at seven years","NA","NA","<E-1. Conduct educational meetings>\n・Staff education: Hosting of training workshops (guidance on methods for respiratory examinations; pulmonary rehabilitation): once per year\n<D-1. Build a coalition>\n・Establishment of medical systems (system of cooperation between hospitals and clinics)\n<F-2. Develop resource sharing agreements>\n・Establishment of medical systems(System of cooperation between hospitals and clinics to refer COPD check-up and diagnosis results)","梶"]
[null,"Taniguchi et al., 2011","Cross-sectional survey ","2,215 nurses who were working in three cancer hospitals and three general hospitals."," Clinical","I-4. Others","Survey items:\n-Tobacco use assessment and documentation\n-Cessation advice\n-Assessment of readiness to quit\n-Individualized explanation of harmful effects of tobacco use\n-Making arrangements for smoking cessation class","NA","NA","NA","NA","梶"]
[null,"Muto et al., 1996","Cross-sectional survey","232 occupational health personnel in the company ","Workplace","PH2-2. Smoke-free policy\n","Survey item:\n-zoning of smoking areas\n-designation of smoking times \n-non-smoking meeting rooms\n-non-smoking offices\n-distribution of pamphlets\n-display of posters \n-Smoking cessation classes","NA","NA","NA","NA","梶"]
[null,"Kadowaki et al., 2006","Retrospective cohort","251 male workers who were smokers and had received a smoking cessation intervention in 1997 in an occupational setting","Workplace","I-2. Behavioral counseling and cessation medication","(1)Face-to-face counseling session with a doctor\n(2)Smoking Cessation Declaration\n(3)Periodic visits to work stations by the doctor and an occupational nurse for encouragement and leaflet distribution, and group discussions.\n(4)A Smoking Cessation Marathon program (distributed a stamp sheet to each of the Smoking Cessation Marathon participants to let them confirm daily cessation)","Smoking cessation rates  at 10, 18, 30, 42, 54, and 66 months after the initial intervention (self-reported)","NA","NA","NA","梶"]
[null,"Takahashi et al., 2006","Prospective cohort (pilot study)","359 smokers who visited one of the respiratory divisions of three hospitals"," Clinical","I-4. Others; \n(phase 1) requested to complete a brief questionnaire of 5As\n(phase 2) additional eight-page pamphlet under the intervention of a doctor’s interview","(1) In phase I, patients were requested to complete a brief questionnaire about the smoking behavior (ask) with a message to quit smoking (advice), intention to quit (assess),  date of cessation if having the intention (assist), and acceptance of scheduled mail questionnaire (arrange).\n(2) In phase II, subsequent patients at the SSH were recruited to compare the effects of an additional eight-page pamphlet under the intervention of a doctor’s interview.","Self-reported abstinence at three months (phase 1,2)","NA","NA","NA","梶"]
[null,"Kitabayashi et al., 2006","Before-after study","256 patients who were treated for chronic schizophremia in a Japanease psychiatric hospital"," Clinical","PH2-4. Smoke-free policies","Smoking prohibition within the institutional buliding of the psychiatric hospital","Smoking rate at three months (self-reported? Not written) ","NA","NA","NA","梶"]
[null,"Higashida et al., 2014","A prospective cohort study","420 pregnant women who attended prenatal examinations at five private clinics"," Clinical","I-4. Others; Feedback of urinary cotinine test results","Urinary cotinine testing and disclosing to pregnant women at a subsequent prenatal examination\n","Percentages of urinary cotinine-positive subjects","NA","NA","NA","梶/湯脇"]
[null,"Tanaka et al., 2006","Prospective cohort","1,017 smokers in the intervention group and 1,290 smokers in the control group","Workplace","I-2. Behavioral counseling and cessation medication\nPH2-2. Public awareness about tobacco consumption risk and benefits of tobacco cessation\n","(1)placing posters with information on smoking cessation at worksites, and placing information on stages of change in smoking cessation behavior on worksite websites and in worksite newsletters\n(2)conducting a six-week worksite smoking cessation campaign that consisted of <1> delivery of five brochures on the stages of change in smoking cessation behavior; <2> four short-term counseling sessions with prescriptions for nicotine patches for 28 days if requested; <3> giving an award to the winner among those who continued to abstain from smoking during the campaign\n(3)providing suggestions to individuals on ways to avoid second-hand smoking and designation of smoking areas by the Safety and Hygiene Committee at the worksites\n・conducting periodic site visits to the designated smoking areas by an expert researcher once a year","Self-reported abstinence at 36 months","NA","NA","<E-6. Distribute educational materials>\nmaterials and technical support provided by our research group","梶"]
[null,"Shinmura et al., 2008","Cross-sectional survey","793 municipal health promotion divisions","Community","PH2-1. Smoke-free policy\nI-1. behavioral counseling and cessation medication","Survey item:\n-smoking cessation support programs \n-programs by medical institutions\n-separation of smoking areas  in municipal facilities\n-total smoking bans in municipal facilities \n-prohibiting smoking on streets or littering\n-publicized the names of non-smoking or smoke-free restaurants","NA","NA","NA","NA","梶"]
[null,"Kadowaki et al., 2000"," Randomized trial","263 male smokers in a radiator manufacturing factory ","Workplace","I-2. Behavioral counseling and cessation medication","(1)Face-to-face counseling session with a doctor\n(2)Smoking Cessation Declaration\n(3)Periodic visits to work stations by the doctor and an occupational nurse for encouragement and leaflet distribution, and group discussions.\n(4)A Smoking Cessation Marathon program (distributed a stamp sheet to each of the Smoking Cessation Marathon participants to let him confirm daily cessation)","Self-reporting of quitting for more than one month","NA","NA","NA","梶"]
[null,"Kano et al., 2007","Prospective cohort (not written) ","・61 smokers out of  municipal government employees\n・46 smokers (employees and students) on a medical campus (Tsurumai Campus) of Nagoya University","Workplace","I-2. Others; genotype notification","Genotype notification","Questionnaires (stage of smokers concerning smoking cessation)  at three months after the enrollment","NA","NA","NA","梶"]
[null,"Kinoshita et al., 2004","Before-after study ","4,221 applicants of three consecutive programs named “STOP SMOKING” CONTEST conducted in 1998, 1999, and 2000","Health checkup center","I-4. Behavioral counseling and cessation medication","(1)Distribution of educational materials (contest )(2)Instructions, self-help book, small readings showing smoking problems\n(3)Submission of reports on smoking cessation, assignment reports on re-smoking prevention\n(4)Rewards (products) for successful quitters",null,"NA","NA","NA"]
[null,"Shimizu et al., 2013","Case study","24 smoking patients who comprise conditions for insurance coverage of smoking cessation treatment"," Clinical","I-4. Behavioral counseling and cessation medication","standard \"Kinengairai\" intervention\nCounseling (smoking cessation status, withdrawal symptoms), measurement of exhaled carbon monoxide concentration, prescription and explanation of smoking cessation medication (varenicline). In principle, patients are seen five times during a 12-week period as an outpatient. ","No desire to smoke and no evidence of smoking again at 12 weeks (self-reported? Not written) ","NA","NA","NA","梶"]
[null,"Hishida et al., 2010","Prospective cohort","562 employees of a bank, who answered that they were a smoker in a questionnaire used for annual health checkups at the workplace ","Workplace","PH1-2. Others; Genotype notification","Genotype notification","Questionnaires (stage of smokers concerning smoking cessation) at three months after the enrollment","NA","NA","NA","梶"]
[null,"Suzuki et al., 2006","Prospective cohort","528 smokers who attempted to stop smoking by participating in smoking cessation programs and whose smoking status was comfirmed at the one-year follow-up","Health center","I-1. Behavioral counseling and cessation medication","Participants were provided with free nicotine patches and referred to medical clinics for follow-up","Self-reported smoking abstinence at the one-year follow-up","NA","NA","NA","湯脇"]
[null,"Iida et al., 2008","Cross-sectional","1,968 preoperative patients"," Clinical","PH2-4. Smoke-free policies","Smoke-free policy","Self-reported smoking status","NA","NA","NA","湯脇"]
[null,"Lee et al., 2003","Cross-sectional","142 occupational physicians at 142 worksites","Workplace","PH2-2. Smoke-free policies\nI-2. Behavioral counseling and cessation medication\n","Survey items:\n-Message promoting smoking cessation\n-Rules on smoking\n-Smoking cessation program\n-No vending machine of cigarette\n-Privilege for non-smoker","NA","NA","NA","NA","湯脇"]
[null,"Shinmura et al., 2004","Cross-sectional","2,570 health promotinon divisions of municipalities ","Community","PH2-1. Smoke-free policies\nI-2. Behavioral counseling and cessation medication\n","Survey items:\n-Partial/complete prohibition of smoking in building\n-Supporting program on smoking cessation\n-Non-smoking time\n-Education activities for secondhand smoking prevention\n-Interaction with the media to spread education and awareness on smoking control program","NA","NA","NA","NA","湯脇"]
[null,"Hamajima et al., 2004","Prospective cohort ","107 municipal government employees, 58 young smokers employed in the previous year and 49 smokers with more than 45 pack-years, who were invited to educational sessions against smoking","Workplace","I-2. Others; Announcement of genotype relating to disease susceptibility of smoking","Announcement of genotype relating to disease susceptibility of smoking","Self-reported abstinence three months after the announcement","NA","NA","NA","湯脇"]
[null,"Utsunomiya et al., 2003","Cross-sectional","315 workplaces (57,051 males and 19,818 females)","Workplace","PH2-2. Smoke-free policies\nI-2. Behavioral counseling and cessation medication\n","Survey items:\n-Restriction of smoking area and/or time\n-Use of educational materials\n-Lecture on the hazard of smoking\n-Award for workers who successfully stopped smoking\n-Tobacco sales in the workplace\n-Individual consultation for smokers\n-Cessation support programs for smokers","Self-reported smoking prevalance","NA","NA","NA","湯脇"]
[null,"Hamajima et al., 2006","Prospective cohort ","101 annual health checkup examinees run by a rural local government in Hokkaido ","Health checkup center","PH1-1. Others; Genotype announcement","Genotype announcement","Self-reported abstinence at one year after the announcement","NA","NA","NA","湯脇"]
[null,"Suzukic et al., 2012","Cross-sectional","43 local government in Osaka prefecture","Community","PH2-2. Smoke-free policies\nI-2. Behavioral counseling and cessation medication\n","Survey items\n-secondhand smoking prevention\n-Smoking cessation program at community health program\n-Supporting program for smoking cessation\n-Access for smoking cessation thrapy\n-Education for smoking prevention and setting up committee for smoking prevention\n-Access to tobacco sales","NA","NA","NA","NA","湯脇"]
[null,"Tamura et al., 2012","Cross-sectional","683 subjects visited the Daiko Medical Center from June 2004 to March 2011 (of these, 43 smokers sought smoking cessation support)"," Clinical","I-4. Others; a nicotine patch or genotyping related to their susceptibility to carcinogens","A nicotine patch or genotyping related to their susceptibility to carcinogens","Self-reported smoking abstinence at three months after first visit","NA","NA","NA","湯脇"]
[null,"Tobari et al., 2010","Randomized trial","Patients with hypertension in the age range of 40-79 years  who visited the Miho Medical Clinic between April 2007 and June 2007."," Clinical","I-4. Others; counseling and goal setting","Monthly pharmacist counseling and setting individual goals of lifestyle modification","Self-reported smoking status at six months","NA","NA","NA","湯脇"]
[null,"Nagao et al., 2022","Nonrandomized prospective cohort ","Current smokers (aged ≥20 years) with an oral potentially malignant disorder or periodontitis and those seeking dental implants."," Clinical","I-4. Behavioral counseling and cessation medication","Tobacco cessation advice\nCounselling\nNicotine replacement therapy","Tobacco abstinence rate at 3, 6, and 12 months evaluated by self-reports and comfirmed by biochemical validation","NA","NA","NA","湯脇"]
[null,"Tomioka et al., 2014","Prospective cohort ","277 consecutive patients who participated in the three-month smoking cessation programme "," Clinical","I-4. Behavioral counseling and cessation medication","Smoking cessation treatment programme","Health-related quality of life at the end of the three-month smoking cessation programme","NA","NA","NA","湯脇/梶"]
[null,"Fujita et al., 2020","Retrospective cohort","3,657 subjects who had quit smoking with varenicline or no pharmacotherapy"," Clinical","I-4. Behavioral counseling and cessation medication","Standard \"Kinengairai\" intervention","Maintenance of smoking cessation for one and two years based on the questionnaire of health examination","NA","NA","NA","湯脇"]
[null,"Kadowaki et al., 2004","Controlled before-after study","1,450 employees in a chemical plant in Hyogo ","Workplace","I-2. Behavioral counseling and cessation medication","One group session, followed by correspondence by postal or in-house mail","Not smoked for more than four weeks, smoking prevalence","NA","NA","<E-6. Distribute educational materials>\nTraining for medical students as a provider","湯脇/今村"]
[null,"Saito et al., 2010","Cross-sectional","93 health professionals (dentist, dental hygienist, and medical)\n"," Clinical","I-4,Others;Advice to quit\n","Survey items\n-Asking smoking status\n-Advice to quit\n-Assess willingness to make a quitting attempt\n-Assist in quitting attempt","NA","NA","NA","NA","湯脇"]
[null,"Isse et al., 2021","Prospective cohort ","Three patients in the smoking cessation treatment, aged 20-69 years\n"," Clinical","I-4. Web or internet-based intervention","Closed Facebook group:\nStaff members were expected to help patients who struggled with the temptation to smoke by using several communication methods such as reflective listening to show attention to the participants by responding to posted messages and confirming understanding of participants’ ideas, and by showing empathy. Successful abstainers were encouraged to support others by offering advice based on their own experiences of coping with difficult situations and maintaining smoking cessation. The Facebook intervention was designed to provide the convenience of peer and clinician access anywhere and anytime to support patients during and after the smoking cessation clinic program.","Self-reported maintenace of smoking cessation for one year","NA","NA","NA","湯脇"]
[null,"Igarashi et al., 2016","Simulation study","NA","Clinicals","I-4. Behavioral counseling and cessation medication","Varenicline, NRT, BMT ","NA","NA","NA","NA","長澤"]
[null,"Hanioka et al., 2010","Randomized trial","Smokers at dental clinics (n=56)","Clinicals","I-4. Behavioral counseling and cessation medication","Intensive intervention of five counseling sessions, including an additional nicotine replacement regimen","Self-reported smoking cessation","NA","NA","NA","長澤"]
[null,"Dohi et al., 2007","Before-after study","1,983 inpatients undergoing surgery who had an arterial puncture or an arterial line in place for collection of arterial blood samples in the operating room.\n"," Clinical","PH2-4. Smoke-free policies","Smoke-free policy","Blood carboxyhemoglobin concentration","NA","NA","NA","湯脇"]
[null,"Hanioka et al., 2007","Non-randomized trial","797 smoking patients aged 20 or older, who agreed to participate\n"," Clinical","I-4. Others; brief explanation regarding dental events relevant to smoking, employing color charts and reminder cards\n","Brief explanation regarding dental events relevant to smoking, employing color charts and reminder cards","The level of changes in smoking behavior","NA","NA","NA","湯脇"]
[null,"Hanioka et al., 2010","Randomized trial","56 patients in dental clinics who had the willingness to stop smoking within one month\n"," Clinical","I-4. Behavioral counseling and cessation medication\n","At the first visit: setting a quit date, providing self-help material and nicotine patches for six weeks with information regarding nicotine gum\nAt first visit and following visit (two, four, eight weeks, and three months after quit date): counseling","Self-reported smoking cessation after 3, 6, and 12 months after first visit, with level of cotinine in saliva","NA","NA","<E-6. Distribute educational materials>\nDentists and dental hygienists in 30 dental clinics participated in\na 3-hour training course of intensive smoking-cessation intervention","湯脇"]
[null,"Hashimoto et al., 2020","Prospective observational registry","NA"," Clinical","I-4. Behavioral counseling and cessation medication\n","Smoking cessation program ","Smoking status (8, 12 weeks)","NA","NA","NA","長澤"]
[null,"Watanabe et al., 2016","Before-after study","NA"," Clinical","I-1. Behavioral counseling and cessation medication\n","Smoking cessation treatment + pharmacotherapy management\nFive standard smoking cessation treatments\n∙ Consultation support from community pharmacist (after 3-10 days of smoking cessation) ∙ Dealing with side effects\nHandbook of smoking cessation medications (information and recent diary)","Smoking cessation rate at 12 weeks","NA","NA","<E-3. Conduct ongoing training>\nFour training sessions for pharmcists for acquiring the contents of the protocol to ensure their knowledge and skills, and their responsibility for implementing the drug therapy in collaboration with physicians","齋藤"]
[null,"Nishina et al., 2015","Intervention study","NA"," Clinical","I-4. Behavioral counseling and cessation medication AND dental examination\n","Smoking cessation program (five visits/12 weeks) and 2 follow-ups (at four and six months)\nDental examination was provided during these six months","Smoking abstinence (four weeks, four months, and six months)","NA","NA","NA","長澤"]
[null,"Higashida et al. ,2014","Prospective cohort study","NA"," Clinical","I-4. Others; Urinary cotinine testing\n","Urinary cotinine testing and a questionnaire survey regarding smoking status, and poster/leaflet on smoking cessation ","Urinary cotinine level","NA","NA","NA","長澤"]
[null,"Ota et al., 2005","Controlled before-after study","88 volunteer smokers who aimed to quit smoking and completed the Quit Smoking Marathon (QSM) program","Internet","I-1. Web or internet-based intervention\n","A one-month smoking cessation program, which consisted of a home page on the world wide web, a mailing list, and daily guidance e-mails from the conductor.\n","Self-reported smoking status six months and one year after the QSM ended.","NA","NA","NA","能城"]
[null,"Nakamura et al., 2004","Intervention study","NA","Workplace","I-2. Behavioral counseling and cessation medication\n","Counselling according to smoking cessation stage at 0, 1, 2, 4 and 6 months","Smoking cessation rate at 6 months","NA","NA","NA","加藤"]
[null,"Muto et al., 1998","Intervention study (quasi-experimental study) ","NA","Workplace","I-2. Behavioral counseling and cessation medication\n","\"SOMKEBUSTERS\" program based on six self-help guide","Abstinence at two weeks, four weeks, two months, three months, six months, and one year (self-reports)","NA","NA","NA","梶"]
[null,"Kawakami et al., 1997","Cross-sectional","NA","Clinical","I-4,Others;Advice to quit\n","Advice on smoking cessation (asking about smoking status, giving advice on cessation, explaining the need for smoking cessation interventions).","NA","NA","NA","NA","梶"]
[null,"Masaki et al., 2020","Randomized trial\n","584 eligible paticipants\n(1)diagnosed with nicotine dependence\n(2) smoking history of pack-years>= 10\n(3)intended to quit smoking immediately\n(4) agreed to participate in a smoking cessation treatment program with written informed consent\n(5)could use a smartphone without difficulty","Community","I-1. Web or internet-based interventions\n","The intervention group used the CureApp Smoking Cessation (CASC) system, and the control group used the control app, each for 24 weeks, in addition to a 12-week standard smoking cessation treatment.","biochemically validated CAR (Continuous abstinence rate )(*)  from weeks 9 to 24\n*(1) the self-reporting of continuous abstinence and (2) an exhaled CO concentration <=10 ppm, measured by medical staff at each clinic visit.)","NA","NA","NA","梶"]
[null,"Miura et al., 1998","Intervention study","789 students (smokers and non-smokers)","School","PH2-3. Public awareness about tobacco consumption risk and benefits of tobacco cessation","Smoking cessation education (video and lectures)","Smoking cessation rate at 3 weeks","NA","NA","NA","齋藤"]
[null,"Onda et al., 2021","Cluster-randomized controlled trial","Smokers recruited at 11 pharmacies (n=24)","Community pharmacy","I-1. Behavioral counseling and cessation medication","Family pharmacist's Intervention for Nicotine Elimination [FINE] program: participating patients met with the pharmacists or talked to them on the phone five times at two- to four-week intervals and received personalized and structured brief smoking cessation advice.","The percentage of participants who had quit smoking at the end of the three-month follow-up period (three-month quit rate)","NA","NA","NA","湯脇"]
[null,"Nagao et al., 2021","Prospective cohort","Current smokers with oral potentially malignant disorders (OPMDs), periodontitis, or those needing a dental implant (n=74)","Outpatient dental clinics","I-4. Behavioral counseling and cessation medication","(i) smoking cessation methods\n(ii) assistance with smoking cessation, a solution strategy during smoking cessation, and use of nicotine replacement therapy (NRT) products\n(iii) brief instructions on smoking cessation\n(iv) components of follow-up (counselling during smoking cessation, positive reinforcement for maintaining smoking cessation, and risk of relapse)\n(v) clinic attendance time required to receive smoking cessation instructions (first and second instructions, less than 15 minutes; third, fourth, and fifth instructions, less than 5 minutes)\n(vi) number of visits required for examination and consultation\n(vii) setting a quit date for smoking cessation","Tobacco abstinence rate at 3, 6, and 12 months","NA","NA","NA","湯脇"]
[null,"Mizuno et al., 2021"," Before-after study","1,502 on-staff oncology nurses who were providing direct patient care in the adult population","Clinicals","PH1-4. Training or awareness  program to health workers","Tobacco dependence interventions in cancer care practice","NA","NA","NA","NA","梶"]
[null,"Sezai et al., 2022","Cross-sectional","682 nursing professionals (public health nurses, midwives, nurse practitioners, and practical nurses) participated in smoking cessation support (SCS) workshops that\nwere held specifically for nursing professionals in 13 prefectures of Japan by the prefectural\nnursing associations.","Clinicals or community","I-4. Behavioral counseling and cessation medication","Smoking cessation support","NA","NA","NA","NA","梶"]
[null,"Fujita et al., 2021","Retrospective cohort study","People (N = 3,635) who quit smoking and completed health examinations every fiscal year from 2012 to 2015.","Clinical","I-4. Behavioral counseling and cessation medication","Varenicline for smoking cessation","Abstinence at one year and two years","NA","NA","NA","梶"]
[null,"Taniguchi et al., 2022","Before-after study","628 nurses participated in the program.","Health or\nprevention workplace or  medical workplace","PH1-4. Training or awareness program to health worker","Six-hour smoking cessation educational program","NA","NA","NA","NA","梶"]
[null,"Mochizuki et al., 2004","Randomized trial","Smokers who visited pharmacies to buy Nicorette (n=28)","Community pharmacy","I-1. Behavioral counseling and cessation medication","Issuance of smoking cessation notes.\nClarification of motivation to quit smoking\nExchange of smoking cessation declarations\nAdvice on withdrawal symptoms\nRegular advice and encouragement by telephone (1, 3, 8 weeks and 3 months after quitting smoking)","Self-reported smoking cessation rate","NA","NA","NA","湯脇"]